- Home
- EQ vs LNZA Comparison
EQ vs LNZA Comparison
Compare EQ & LNZA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- LNZA
- Stock Information
- Founded
- EQ 2017
- LNZA 2005
- Country
- EQ United States
- LNZA United States
- Employees
- EQ N/A
- LNZA N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- LNZA Major Chemicals
- Sector
- EQ Health Care
- LNZA Industrials
- Exchange
- EQ Nasdaq
- LNZA Nasdaq
- Market Cap
- EQ 85.1M
- LNZA 98.1M
- IPO Year
- EQ 2018
- LNZA N/A
- Fundamental
- Price
- EQ $1.34
- LNZA $26.57
- Analyst Decision
- EQ Hold
- LNZA Hold
- Analyst Count
- EQ 2
- LNZA 2
- Target Price
- EQ $1.00
- LNZA $200.00
- AVG Volume (30 Days)
- EQ 725.3K
- LNZA 34.0K
- Earning Date
- EQ 11-12-2025
- LNZA 11-07-2025
- Dividend Yield
- EQ N/A
- LNZA N/A
- EPS Growth
- EQ N/A
- LNZA N/A
- EPS
- EQ N/A
- LNZA N/A
- Revenue
- EQ $16,553,000.00
- LNZA $40,540,000.00
- Revenue This Year
- EQ N/A
- LNZA N/A
- Revenue Next Year
- EQ N/A
- LNZA $86.24
- P/E Ratio
- EQ N/A
- LNZA N/A
- Revenue Growth
- EQ N/A
- LNZA N/A
- 52 Week Low
- EQ $0.27
- LNZA $14.01
- 52 Week High
- EQ $2.35
- LNZA $274.00
- Technical
- Relative Strength Index (RSI)
- EQ 43.10
- LNZA 60.90
- Support Level
- EQ $1.41
- LNZA $23.64
- Resistance Level
- EQ $1.64
- LNZA $31.50
- Average True Range (ATR)
- EQ 0.11
- LNZA 3.35
- MACD
- EQ -0.02
- LNZA -0.00
- Stochastic Oscillator
- EQ 9.11
- LNZA 63.86
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
About LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a carbon management company transforming waste carbon into sustainable fuels, fabrics, packaging, and nutrition. Its goal is to advance a circular economy where carbon is reused rather than wasted, reducing reliance on virgin fossil resources and supporting supply chain resilience. The company operates in North America, Europe, Middle East, Africa (EMEA), Asia, and Australia.